Our business idea is to help people with chronic conditions and illnesses by using a patented treatment method that is neither surgical nor drug-based. The treatment is called Kinetic Oscillation Stimulation and is abbreviated K.O.S.
Today, we focus on chronic nasal congestion (rhinitis) which affects about 1.3 percent of the world’s population, and partly on chronic migraines that affect 1.4-2.2 percent of the population with severe and frequent headaches.
K.O.S is a product system for neurostimulation therapy with long-term effects, which modulates the autonomic nervous system functions. The rhinitis treatment is CE-certified and is sold in the EU. The migraine treatment is in a clinical trial phase, but was CE marked in May 2021 based on interim analysis data – and therefore currently under market introduction.
We want to establish our technology in the international market for neuromodulation. We sell our product system and our treatments through distributors to clinics and hospitals, who in turn treat the patients.
Today, the company has three employees, supported by a handful of expert consultants with extensive overall experience in medical technology product development, international market establishment, and clinical study activities. The business is entirely focused on sales in a few selected markets and the implementation of the two ongoing studies.
Chordate Medical AB, the Group’s operating company, is a wholly owned subsidiary of Chordate Medical Holding AB (Publ), was listed on Nordic Growth Market-SME on March 8, 2017 and is since February 15, 2022, traded on Nasdaq First North Growth Market.
The company is based in Kista, outside Stockholm.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.